Allen C Ho

Dr. Allen C Ho

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Ophthalmology
Verified
Journal Article
Closed access
WSWasim A. Samara
Wasim A. Samara
ASAbtin Shahlaee
Abtin Shahlaee
MAMurtaza K. Adam
Murtaza K. Adam
MKM. Ali Khan
M. Ali Khan
ACAllen Chiang
Allen Chiang
AHAllen C Ho
Allen C Ho

1 November 2014 in Ophthalmology
Verified
Journal Article
Open access
AHAllen C Ho
Allen C Ho
BBBrandon G. Busbee
Brandon G. Busbee
CRCarl D. Regillo
Carl D. Regillo
MWMark R. Wieland
Mark R. Wieland
SESherri A. Van Everen
Sherri A. Van Everen
PLPhillip Lai
Phillip Lai
To evaluate the 24-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg administered monthly or as needed (pro re nata [PRN]) in patients with neovascular age-related macular degeneration (wet AMD). Twenty-four-month, multicenter, randomized, double-masked, active treatment-controlled phase 3 trial. Patients (n = 1098) ≥ 50 years of age with treatment-naïve subfoveal wet AMD. Patients were randomized to receive intravitreal injections of ranibizumab 0.5 mg or 2.0 mg monthly or PRN after 3 monthly loading doses. The primary efficacy end point was the mean change in best-corrected visual acuity (BCVA) from baseline at month 12. Key secondary end points included mean change in BCVA from baseline at month 24, proportion of patients who gained ≥ 15 letters in BCVA, mean number of ranibizumab injections, and mean change in central foveal thickness from baseline over time by spectral-domain optical coherence tomography. Ocular and systemic safety events also were evaluated through month 24. At month 24, the mean change from baseline in BCVA was (letters) +9.1 (0.5 mg monthly), +7.9 (0.5 mg PRN), +8.0 (2.0 mg monthly), and +7.6 (2.0 mg PRN). The change in mean BCVA from month 12 to 24 was (letters) -1.0, -0.3, -1.2, and -1.0, respectively. The proportion of patients who gained ≥ 15 letters from baseline in BCVA at month 24 was 34.5%, 33.1%, 37.6%, and 34.8%, respectively. The mean number of ranibizumab injections through month 24 was 21.4, 13.3, 21.6, and 11.2, respectively; 5.6 and 4.3 mean injections were required in year 2 in the 0.5 mg and 2.0 mg PRN groups, respectively. The average treatment interval in the 0.5 mg PRN group was 9.9 weeks after 3 monthly loading doses, and 93% of these patients did not require monthly dosing. Ocular and systemic safety profiles over 2 years were similar among all 4 treatment groups and were consistent with previous ranibizumab trials in AMD. At month 24, mean BCVA improvements were clinically meaningful and similar among all 4 ranibizumab treatment groups. The 0.5 mg PRN group achieved a mean gain of 7.9 letters at month 24 with an average of 13.3 injections (5.6 injections in year 2). No new safety events were identified over 24 months.

1 August 2015 in Ophthalmology
Verified
Journal Article
Open access
AHAllen C Ho
Allen C Ho
MHMark S. Humayun
Mark S. Humayun
JDJessy D. Dorn
Jessy D. Dorn
LCLyndon da Cruz
Lyndon da Cruz
GDGislin Dagnelie
Gislin Dagnelie
RGRobert J. Greenberg
Robert J. Greenberg
Retinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of this clinical trial was to evaluate the safety, reliability, and benefit of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) in restoring some visual function to subjects completely blind from RP. We report clinical trial results at 1 and 3 years after implantation. The study is a multicenter, single-arm, prospective clinical trial. There were 30 subjects in 10 centers in the United States and Europe. Subjects served as their own controls, that is, implanted eye versus fellow eye, and system on versus system off (native residual vision). The Argus II System was implanted on and in a single eye (typically the worse-seeing eye) of blind subjects. Subjects wore glasses mounted with a small camera and a video processor that converted images into stimulation patterns sent to the electrode array on the retina. The primary outcome measures were safety (the number, seriousness, and relatedness of adverse events) and visual function, as measured by 3 computer-based, objective tests. A total of 29 of 30 subjects had functioning Argus II Systems implants 3 years after implantation. Eleven subjects experienced a total of 23 serious device- or surgery-related adverse events. All were treated with standard ophthalmic care. As a group, subjects performed significantly better with the system on than off on all visual function tests and functional vision assessments. The 3-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind from RP. Earlier results from this trial were used to gain approval of the Argus II by the Food and Drug Administration and a CE mark in Europe. The Argus II System is the first and only retinal implant to have both approvals.

1 January 2016 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ASAbtin Shahlaee
Abtin Shahlaee
MPMaria Pefkianaki
Maria Pefkianaki
JHJason Hsu
Jason Hsu
AHAllen C Ho
Allen C Ho

1 May 2016 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ASAbtin Shahlaee
Abtin Shahlaee
WSWasim A. Samara
Wasim A. Samara
JHJason Hsu
Jason Hsu
ESEmil Anthony T. Say
Emil Anthony T. Say
MKM. Ali Khan
M. Ali Khan
AHAllen C Ho
Allen C Ho

4 April 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SRStephen R. Russell
Stephen R. Russell
ADArlene V. Drack
Arlene V. Drack
Artur CideciyanArtur Cideciyan
Artur Cideciyan
SJSamuel Jacobson
Samuel Jacobson
BLBart Peter Leroy
Bart Peter Leroy
AGAniz Girach
Aniz Girach
CEP290-associated Leber congenital amaurosis type 10 (LCA10) is a retinal disease resulting in childhood blindness. Sepofarsen is an RNA antisense oligonucleotide targeting the c.2991+1655A>G variant in the CEP290 gene to treat LCA10. In this open-label, phase 1b/2 (NCT03140969), 12-month, multicenter, multiple-dose, dose-escalation trial, six adult patients and five pediatric patients received ≤4 doses of intravitreal sepofarsen into the worse-seeing eye. The primary objective was to evaluate sepofarsen safety and tolerability via the frequency and severity of ocular adverse events (AEs); secondary objectives were to evaluate pharmacokinetics and efficacy via changes in functional outcomes. Six patients received sepofarsen 160 µg/80 µg, and five patients received sepofarsen 320 µg/160 µg. Ten of 11 (90.9%) patients developed ocular AEs in the treated eye (5/6 with 160 µg/80 µg; 5/5 with 320 µg/160 µg) versus one of 11 (9.1%) in the untreated eye; most were mild in severity and dose dependent. Eight patients developed cataracts, of which six (75.0%) were categorized as serious (2/3 with 160 µg/80 µg; 4/5 with 320 µg/160 µg), as lens replacement was required. As the 160-µg/80-µg group showed a better benefit–risk profile, higher doses were discontinued or not initiated. Statistically significant improvements in visual acuity and retinal sensitivity were reported (post hoc analysis). The manageable safety profile and improvements reported in this trial support the continuation of sepofarsen development.